全文获取类型
收费全文 | 480篇 |
免费 | 20篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 25篇 |
妇产科学 | 6篇 |
基础医学 | 45篇 |
口腔科学 | 11篇 |
临床医学 | 33篇 |
内科学 | 132篇 |
皮肤病学 | 38篇 |
神经病学 | 36篇 |
外科学 | 71篇 |
综合类 | 3篇 |
预防医学 | 5篇 |
眼科学 | 2篇 |
药学 | 55篇 |
中国医学 | 2篇 |
肿瘤学 | 35篇 |
出版年
2022年 | 2篇 |
2021年 | 7篇 |
2020年 | 2篇 |
2017年 | 5篇 |
2016年 | 6篇 |
2015年 | 10篇 |
2014年 | 10篇 |
2013年 | 7篇 |
2012年 | 14篇 |
2010年 | 17篇 |
2009年 | 11篇 |
2008年 | 9篇 |
2007年 | 7篇 |
2006年 | 26篇 |
2005年 | 6篇 |
2004年 | 10篇 |
2003年 | 7篇 |
2002年 | 7篇 |
2001年 | 6篇 |
2000年 | 2篇 |
1999年 | 13篇 |
1998年 | 31篇 |
1997年 | 38篇 |
1996年 | 30篇 |
1995年 | 27篇 |
1994年 | 19篇 |
1993年 | 10篇 |
1992年 | 8篇 |
1991年 | 11篇 |
1990年 | 6篇 |
1989年 | 5篇 |
1988年 | 4篇 |
1987年 | 2篇 |
1986年 | 5篇 |
1985年 | 3篇 |
1984年 | 4篇 |
1983年 | 4篇 |
1981年 | 3篇 |
1980年 | 2篇 |
1979年 | 4篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1975年 | 2篇 |
1973年 | 2篇 |
1959年 | 12篇 |
1958年 | 12篇 |
1957年 | 13篇 |
1956年 | 20篇 |
1955年 | 16篇 |
1954年 | 14篇 |
排序方式: 共有500条查询结果,搜索用时 15 毫秒
111.
皮肤不同层对脂溶性药物经皮渗透的影响 总被引:4,自引:0,他引:4
目的 评价皮肤角质层和真皮层对药物经皮渗透的影响。方法 选择 5 氟尿嘧啶 ,茶碱 ,氢醌 ,巴比妥 ,硝酸异山梨酯和酮基布洛芬共 6种具不同脂溶性的药物 ,以贴片为试验药剂 ,采用改进Franz扩散池法 ,考察药物经完整皮肤和剥离角质层皮肤的体外透皮能力。结果 药物的脂溶性LogPc和药物经完整或角质层剥离皮肤的透皮能力 (Kp ,cm·h-1)间均具有抛物线关系。然而 ,角质层剥离后 ,药物Kp增加率主要同药物在水中的溶解度有关。渗透促进剂肉豆蔻酸异丙酯 (IPM )加入到贴片中后 ,药物的脂溶性LogPc和其Kp间无抛物线关系。药物经完整皮肤渗透时 ,因加入IPM而引起的Kp增加率随药物LogPc的变小而增加。药物经角质层剥离皮肤渗透时 ,因加入IPM而引起的Kp增加率随药物在IPM中的溶解度增大而增加。结论 本实验为皮肤病态条件 ,如皮肤受伤或溃疡等时药物经皮渗透规律研究提供一种新的方法 相似文献
112.
Mechanism for Species-Specific Induction of Leydig Cell Tumors in Rats by Lansoprazole 总被引:1,自引:1,他引:0
FORT F. L.; MIYAJIMA H.; ANDO T.; SUZUKI T.; YAMAMOTO M.; HAMASHIMA T.; SATO S.; KITAZAKI T.; MAHONY M. C.; HODGEN G. D. 《Toxicological sciences》1995,26(2):191-202
Lansoprazole is a substituted benzimidazole which inhibits gastricacid secretion by inhibiting the hydrogen-potassium ATPase (protonpump) in the parietal cell. The finding of Leydig cell hyperplasiaand Leydig cell tumors in 2-year oral studies in Sprague-Dawleyrats but not in CD-1 mice prompted investigative studies todetermine the mechanism for the Leydig cell changes. hCG challengestudies in Sprague-Dawley rats revealed decreased testosteroneresponsiveness in rats treated orally for 1 or 2 weeks withlansoprazole. After 4 weeks of daily oral treatment increasesin serum LH and decreases in serum testosterone were detectedwithin a few hours after dosing. In a study where 9-month-oldmale F344 rats were given testosterone supplementation via Silasticimplants and then treated with lansoprazole for 6 months, ahigh incidence of Leydig cell tumors was seen in lansoprazoletreated,unsupplemented rats, whereas no Leydig cell tumors were seenin testosterone supplemented rats. This implied that reductionof the normal feedback inhibition at the level of the hypothalaumsand/or pituitary due to reduced testosterone levels, thus givingrise to elevated levels of LH, was involved in the inductionof Leydig cell tumors by lansoprazole. In vitro studies withLeydig cells from rats using various stimulators and precursorsof testosterone biosynthesis demonstrated that the most sensitivesite for inhibition of testosterone synthesis by lansoprazoleis the transport of cholesterol to the cholesterol side chaincleavage enzyme. The IC50s for inhibition of LH or hCG-stimulatedtestosterone synthesis in Leydig cells from rats, mice, andmonkeys were 1112, 8, and 27.4 µg/ml, respectively.In vitro studies with metabolites of lansoprazole revealed thatthree metabolites were more potent inhibitors of testosteronesynthesis than the parent drug, two of them being at least 10times more potent. These metabolites are present in rats atsubstantial levels but are undetectable in humans. The lackof induction of Leydig cell tumors in mice, lower sensitivityof primate Leydig cells, and the absence of testosterone synthesisinhibitingmetabolites in man suggest that Leydig cell tumors found inrats represent a species-specific sensitivity and does not implya risk for clinical use in man. 相似文献
113.
Giant hepatic angiomyolipoma 总被引:1,自引:0,他引:1
T. OHMORI N. ARITA N. URAGA R. TABEI M. YAMAMOTO M. KATAOKA K. HAMAMOTO 《Histopathology》1989,15(5):540-543
114.
115.
Efficacy and Safety of Apixaban in the Patients Undergoing the Ablation of Atrial Fibrillation
下载免费PDF全文
![点击此处可从《Pacing and clinical electrophysiology : PACE》网站下载免费的PDF全文](/ch/ext_images/free.gif)
TOMOYUKI NAGAO M.D. YASUYA INDEN M.D. Ph.D. MASAYUKI SHIMANO M.D. Ph.D. MASAYA FUJITA M.D. SATOSHI YANAGISAWA M.D. HIROYUKI KATO M.D. SHINJI ISHIKAWA M.D. AYA MIYOSHI M.D. SATOSHI OKUMURA M.D. SHIOU OHGUCHI M.D. TOSHIHIKO YAMAMOTO M.D. NAOKI YOSHIDA M.D. Ph.D. MAKOTO HIRAI M.D. Ph.D. TOYOAKI MUROHARA M.D. Ph.D. 《Pacing and clinical electrophysiology : PACE》2015,38(2):155-163
116.
117.
Minoru HASEGAWA Hidemitsu ORITO Keiko YAMAMOTO Takashi MATSUSHITA Yasuhito HAMAGUCHI Manabu FUJIMOTO Kazuhiko TAKEHARA 《The Journal of dermatology》2012,39(11):922-926
We report a case of a 64‐year‐old man with POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) syndrome that had been previously misdiagnosed as systemic sclerosis. He had typical symptoms of POEMS syndrome, however, the existence of skin sclerosis, contracture of fingers and pigmentation were similar to that of systemic sclerosis. Ten patients, including the patient discussed in this case, visited our department between 1990 and 2011. Among them, five patients had skin sclerosis. Therefore, we compared skin lesions and clinical/laboratory features of POEMS syndrome and systemic sclerosis in an attempt to distinguish these disorders. Regarding the cutaneous and laboratory findings, the existence of hemangioma or hypertrichosis is indicative of POEMS syndrome. By contrast, the existence of systemic sclerosis‐specific autoantibodies, nail fold bleeding, digital ulcer/digital pitting scar or telangiectasia is highly suggestive of systemic sclerosis. To our knowledge, this is the first report to discuss in detail the differentiation between POEMS syndrome and systemic sclerosis. 相似文献
118.
Ken OHTA Terumasa MIYAMOTO Taro AMAGASAKI Manabu YAMAMOTO on behalf of the Study Group 《Respirology (Carlton, Vic.)》2009,14(8):1156-1165
Background and objective: The efficacy and safety of the anti-IgE antibody, omalizumab, has been widely studied in patients with asthma. However to date, no large studies have been performed in Asian populations. The aim of this study was to compare the efficacy and safety of omalizumab with placebo, as add-on therapy in Asian patients with moderate-to-severe persistent asthma.
Methods: Japanese patients (20–75 years of age) with uncontrolled asthma, despite receiving high-dose inhaled corticosteroids and other standard therapies, were randomized to receive add-on treatment with omalizumab or placebo in a 16-week, double-blind, parallel-group, multicentre study.
Results: Altogether, 315 treated patients were included in the efficacy and safety analyses. The change from baseline in morning PEF was 15.45 L/min (least squares mean) with omalizumab versus 2.25 L/min with placebo, a statistically significant difference of 13.19 L/min ( P = 0.0004). Clinically significant asthma exacerbations occurred in six patients (4.0%) treated with omalizumab and in 18 patients (11.0%) treated with placebo. The odds ratio for the risk of experiencing an asthma exacerbation was 0.32 in favour of omalizumab ( P = 0.0192). Changes in asthma symptom scores, daily life activity scores, sleep scores and rescue medication use were in favour of omalizumab, but group differences did not reach statistical significance. Adverse event rates were similar between omalizumab and placebo, except for injection site reactions, which were more frequently observed in the omalizumab group.
Conclusions: Add-on treatment with omalizumab improved asthma control without significant adverse events in Japanese patients with moderate-to-severe persistent asthma. 相似文献
Methods: Japanese patients (20–75 years of age) with uncontrolled asthma, despite receiving high-dose inhaled corticosteroids and other standard therapies, were randomized to receive add-on treatment with omalizumab or placebo in a 16-week, double-blind, parallel-group, multicentre study.
Results: Altogether, 315 treated patients were included in the efficacy and safety analyses. The change from baseline in morning PEF was 15.45 L/min (least squares mean) with omalizumab versus 2.25 L/min with placebo, a statistically significant difference of 13.19 L/min ( P = 0.0004). Clinically significant asthma exacerbations occurred in six patients (4.0%) treated with omalizumab and in 18 patients (11.0%) treated with placebo. The odds ratio for the risk of experiencing an asthma exacerbation was 0.32 in favour of omalizumab ( P = 0.0192). Changes in asthma symptom scores, daily life activity scores, sleep scores and rescue medication use were in favour of omalizumab, but group differences did not reach statistical significance. Adverse event rates were similar between omalizumab and placebo, except for injection site reactions, which were more frequently observed in the omalizumab group.
Conclusions: Add-on treatment with omalizumab improved asthma control without significant adverse events in Japanese patients with moderate-to-severe persistent asthma. 相似文献
119.
Nobuhiro MIKUNI Naotaka USUI Hiroshi OTSUBO Kensuke KAWAI Haruhiko KISHIMA Taketoshi MAEHARA Seiichiro MINE Takamichi YAMAMOTO 《Neurologia medico-chirurgica》2021,61(11):619
This study investigated the number of epilepsy surgeries performed over time in Japan, and conducted a questionnaire survey of the Japan Neurosurgical Society (JNS) training program core hospitals to determine the current status and future objectives of surgical therapies and epilepsy training programs for physicians in Japan. This article presents part of a presentation delivered as a presidential address at the 44th Annual Meeting of the Epilepsy Surgery Society of Japan held in January 2021. The number of epilepsy surgeries performed per year has increased in Japan since 2011 to around 1,200 annually between 2015 and 2018. The questionnaire survey showed that 50% of the responding hospitals performed epilepsy surgery and 29% had an epilepsy center, and that these hospitals provided senior residents with education regarding epilepsy surgery. The presence of an epilepsy center in a hospital was positively correlated with the availability of long-term video electroencephalography monitoring beds as well as the number of epilepsy surgeries performed at the hospital. In regions with no medical facilities offering specialized surgical therapies for epilepsy, the JNS training program core hospitals may help improve epilepsy diagnosis and treatment. They may also increase the number of safe and effective surgeries by establishing epilepsy centers that can perform long-term video electroencephalography monitoring, providing junior neurosurgeons with training regarding epilepsy, and playing a core role in surgical therapies for epilepsy in tertiary medical areas in close cooperation with neighboring medical facilities. 相似文献
120.
Toshiyuki YAMAMOTO 《The Journal of dermatology》2010,37(1):26-41
Scleroderma is a fibrotic condition characterized by immunological abnormalities, vascular injury and increased accumulation of extracellular matrix proteins in the skin. Although the etiology of scleroderma has not yet been fully elucidated, a growing body of evidence suggests that extracellular matrix overproduction by activated fibroblasts results from a complex interaction among endothelial cells, lymphocytes, macrophages and fibroblasts, through a number of mediators, such as cytokines, chemokines and growth factors. For a better understanding of the pathophysiology of scleroderma, animal models are important tools. These models reproduce several histological as well as biochemical aspects of human scleroderma, and we can learn a lot through animal studies. On the other hand, it must be emphasized that studying animal models cannot answer all the problems of human scleroderma. In this review, I introduce current insights into the pathogenesis and also recent updates of therapeutic approaches using several animal models of SSc, and discuss their contribution to our understanding of the pathogenesis of, and treatments for, human scleroderma. 相似文献